The present invention involves early prediction of progression of a cancer disease in patients treated for cancer. According to the invention the binding response level of an immunoreactive material (IM) comprising thymidine kinase 1 (TK1) protein is determined in a body fluid sample of a patient and the likelihood of progress of the cancer disease is estimated based directly on this determined IM binding response level. Those patients that run a risk of cancer progress and tumor relapse 1-15 years after the cancer treatment may be identified directly by the IM binding response level according to the invention within a few months following initiation of the treatment.
申请公布号
WO2004100760(A1)
申请公布日期
2004.11.25
申请号
WO2004SE00750
申请日期
2004.05.14
申请人
XI BAO RESEARCH AB;SKOG, SVEN;ERIKSSON, STAFFAN;TRIBUKAIT, BERNHARD;HE, QIMIN